A 6-month longitudinal study of early-onset tardive dyskinesia: Association with olanzapine treatment and mild cognitive impairment in an elderly woman [4]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 2, 2007, Pages 210-212

  Yetimalar, Yeşim ^a   Seçil, Yaprak ^a   Eren, Şölen ^a   Başoǧlu, Mustafa ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; DIAZEPAM; GABAPENTIN; MEMANTINE; OLANZAPINE; QUETIAPINE; VALPROIC ACID;

AGED; ANAMNESIS; CASE REPORT; COGNITIVE DEFECT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LETTER; LONGITUDINAL STUDY; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PHYSICIAN; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION DISORDERS; DIBENZOTHIAZEPINES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 34247170513     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000248621.42165.e8     Document Type: Letter

References (15)

1. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17:47-62.
2. Marder SR, Essock SM, Miller AL, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull. 2002;28:5-16.
3. Segman RH, Lerer B. Genetic factors underlying drug induced tardive dyskinesia. In: Lerer B, ed. Pharmacogenetics of Psychotropic Drugs. Cambridge: Cambridge University Press; 2002.
4. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
5. Ozdemir V, Aklillu E, Mee S, et al. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother. 2006;7:119-133.
6. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging. 2000;17:363-384.
7. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65(suppl 9):21-24.
8. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16:23-45.
9. Chen JJ, Lee KL. Nonparkinsonism movement disorders in the elderly. Consult Pharm. 2006;21:58-71.
10. Navarro B, Montejo A, Martin M. Utility of quetiapine in tardive dyskinesias. Actas Esp Psiquiatr. 2003;31:347-352.
11. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50:703-714.
12. Caroff SN, Campbell EC, Havey J, et al. Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry. 2001;62:772-775.
13. Tammenmaa IA, Sailas E, Mc Grath JJ, et al. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1099-1107.
14. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: Pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50:541-547.
15. Konitsiotis S, Tsironis C, Kiortsis DN, Evangelou A. Effects of N-methyl-D:-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias. Psychopharmacology. 2006;185:369-377.